The Effects of Dupilumab on Allergic Contact Dermatitis

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

NCT03428646 ·Status: ACTIVE_NOT_RECRUITING

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

NCT03389893 ·Status: TERMINATED ·Phase: PHASE4

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

NCT01979016 ·Status: COMPLETED ·Phase: PHASE2

A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

NCT02395133 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03912259 ·Status: COMPLETED ·Phase: PHASE3

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

NCT01385657 ·Status: COMPLETED ·Phase: PHASE1

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT01859988 ·Status: COMPLETED ·Phase: PHASE2

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

NCT04287608 ·Status: COMPLETED

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277769 ·Status: COMPLETED ·Phase: PHASE3

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

NCT02210780 ·Status: COMPLETED ·Phase: PHASE2

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

NCT05265234 ·Status: UNKNOWN ·Phase: PHASE4

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

NCT03054428 ·Status: COMPLETED ·Phase: PHASE3

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

NCT03050151 ·Status: COMPLETED ·Phase: PHASE1

Dupilumab Impact on Skin Resident Memory T Cells

NCT03983460 ·Status: UNKNOWN ·Phase: NA

Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)

NCT01639040 ·Status: COMPLETED ·Phase: PHASE2

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

NCT06881251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

NCT05983068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

NCT04447417 ·Status: COMPLETED ·Phase: PHASE4

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03738397 ·Status: COMPLETED ·Phase: PHASE3

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

NCT04823130 ·Status: COMPLETED ·Phase: PHASE4

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

NCT04033367 ·Status: COMPLETED ·Phase: PHASE4

An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis

NCT04520308 ·Status: UNKNOWN ·Phase: PHASE4

A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab

NCT06169527 ·Status: ACTIVE_NOT_RECRUITING

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

NCT02612454 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3